These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 7903906)

  • 1. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
    Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer.
    deMagalhaes-Silverman M; Rybka WB; Lembersky B; Bloom EJ; Lister J; Pincus SM; Voloshin M; Wilson J; Ball ED
    Am J Clin Oncol; 1996 Apr; 19(2):169-73. PubMed ID: 8610643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW; Pang YK; Tsang YC; Wong SW
    Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
    Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
    Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
    Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
    Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
    Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
    Long GD; Chao NJ; Hu WW; Negrin RS; Wong RM; Blume KG
    Cancer; 1996 Dec; 78(12):2502-9. PubMed ID: 8952558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
    Somlo G; Sniecinski I; Odom-Maryon T; Nowicki B; Chow W; Hamasaki V; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Tetef M; Molina A; Berenson RJ; Forman SJ; Doroshow JH
    Blood; 1997 Mar; 89(5):1521-8. PubMed ID: 9057632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.